Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02541123 · ClinicalTrials.gov registry record
Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma
A clinical trial, sponsored by Banyan Biomarkers.
- Completed
- Registry status
- 194
- Enrollment target
NCT02541123 is a clinical trial that has completed, run by Banyan Biomarkers. The registered enrollment target is 194 participants.
The verdict
NCT02541123 has completed, sponsored by Banyan Biomarkers.
- COMPLETED
- Registry status
- 194 participants
- Enrollment target
Study Summary
The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale score 13-15 as well as in a group of uninjured control subjects.
Interventions
- OTHER Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02541123
The ClinicalTrials.gov registry entry for NCT02541123 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 194 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Banyan Biomarkers, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT02541123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02541123 about?
NCT02541123 is a clinical study titled "Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma". The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale s...
What is the current status of trial NCT02541123?
This trial is currently completed. The enrollment target is 194 participants. The study started on 2016-01. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT02541123?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT02541123?
This trial is sponsored by Banyan Biomarkers, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.